Basiliximab
- Generic Name
- Basiliximab
- Brand Names
- Simulect
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 179045-86-4
- Unique Ingredient Identifier
- 9927MT646M
- Background
A recombinant chimeric (murine/human) monoclonal antibody (IgG1k) that functions as an immunosuppressive agent, specifically binding to and blocking the interleukin-2 receptor a-chain (IL-2R alpha, also known as CD25 antigen) on the surface of activated T-lymphocytes. It is a 144 kDa glycoprotein obtained from fermentation of an established mouse myeloma cel...
- Indication
For prophylactic treatment of kidney transplant rejection
- Associated Conditions
- Rejection Acute Renal
- Associated Therapies
- -
A Study to Evaluate Efalizumab Compared With Cyclosporine As an Immunosuppressant Regimen in De Novo Renal Transplantation
- Conditions
- Interventions
- First Posted Date
- 2008-08-07
- Last Posted Date
- 2017-06-22
- Lead Sponsor
- Genentech, Inc.
- Registration Number
- NCT00729768
Concentration Controlled Everolimus With Reduced Dose Cyclosporine Versus Mycophenolate Mofetil With Standard Dose Cyclosporine in de Novo Renal Transplant Adult Recipients Treated With Basiliximab and Corticosteroids
- Conditions
- Interventions
- First Posted Date
- 2008-04-15
- Last Posted Date
- 2013-06-21
- Lead Sponsor
- Novartis
- Target Recruit Count
- 122
- Registration Number
- NCT00658320
- Locations
- 🇯🇵
Novartis Pharma K.K., Japan, Tokyo, Japan
The Safety and Efficacy of Basiliximab as Maintenance Therapy in Subjects With Stable, Noninfectious Uveitis
- First Posted Date
- 2008-03-28
- Last Posted Date
- 2010-08-19
- Lead Sponsor
- Cerimon Pharmaceuticals
- Target Recruit Count
- 5
- Registration Number
- NCT00646425
- Locations
- 🇺🇸
Ocular Immunology & Uveitis Foundation, Cambridge, Massachusetts, United States
🇺🇸New York Eye and Ear Infirmary, New York, New York, United States
🇺🇸Tauber Eye Center, Kansas City, Missouri, United States
Evaluation of Early Conversion to Everolimus From Cyclosporine in de Novo Renal Transplant Recipients
- Conditions
- Interventions
- First Posted Date
- 2008-03-13
- Last Posted Date
- 2014-08-13
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 204
- Registration Number
- NCT00634920
- Locations
- 🇸🇪
Novartis Investigative Site, Uppsala, Sweden
Basiliximab in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Undergoing Targeted Immunotherapy and Temozolomide-Caused Lymphopenia
- Conditions
- Interventions
- First Posted Date
- 2008-02-29
- Last Posted Date
- 2021-03-09
- Lead Sponsor
- Gary Archer Ph.D.
- Target Recruit Count
- 34
- Registration Number
- NCT00626483
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
In-Vivo Activated T-Cell Depletion to Prevent GVHD
- First Posted Date
- 2008-01-15
- Last Posted Date
- 2014-10-06
- Lead Sponsor
- Indiana University
- Target Recruit Count
- 10
- Registration Number
- NCT00594308
- Locations
- 🇺🇸
Indiana Universtiy Simon Cancer Center, Indianapolis, Indiana, United States
Basiliximab for the Treatment of Acute Graft-versus-host Disease After Allogeneic Stem Cell Transplantation
- Conditions
- First Posted Date
- 2007-11-26
- Last Posted Date
- 2010-07-07
- Lead Sponsor
- Hospital Authority, Hong Kong
- Target Recruit Count
- 60
- Registration Number
- NCT00563108
- Locations
- 🇨🇳
The University of Hong Kong, Hong Kong, China
Belatacept in Liver Transplant Recipients
- First Posted Date
- 2007-11-08
- Last Posted Date
- 2012-10-18
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 260
- Registration Number
- NCT00555321
- Locations
- 🇺🇸
Usc University Hospital, Los Angeles, California, United States
🇺🇸Westchester Medical Center, Valhalla, New York, United States
🇺🇸Baylor University Medical Center, Dallas, Texas, United States
A Study to Assess the Safety and Efficacy of Alefacept in Kidney Transplant Recipients
- Conditions
- Interventions
- First Posted Date
- 2007-10-15
- Last Posted Date
- 2015-12-11
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 323
- Registration Number
- NCT00543569
- Locations
- 🇺🇸
University of North Carolina, Chapel Hill, North Carolina, United States
🇺🇸University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸Methodist University Hospital - Memphis, Memphis, Tennessee, United States
Strategies to Improve Islet Survival
- Conditions
- Interventions
- First Posted Date
- 2007-04-23
- Last Posted Date
- 2016-04-26
- Target Recruit Count
- 5
- Registration Number
- NCT00464555
- Locations
- 🇺🇸
University of Illinois at Chicago, Chicago, Illinois, United States
🇺🇸University of Miami, Miami, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.